会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明专利
    • Antitumor agents having antimitotic and tubulin polymerization inhibiting action, comprising new or known 2-acyl-indole derivatives or aza analogs
    • DE10020852A1
    • 2001-10-31
    • DE10020852
    • 2000-04-28
    • ASTA MEDICA AG
    • BECKERS THOMASBAASNER SILKEKLENNER THOMASMAHBOOBI SIAVOSHPONGRATZ HERWIGFRIESER MARKUSHUFSKY HARALDHOCKEMEYER JOERGFIEBIG HEINZ-HERBERTBURGER ANGELIKABOEHMER FRANK-D
    • A61K31/404A61K31/437A61K31/4439A61K31/4709C07D209/42A61K31/52C07D401/02C07D471/04C07D487/04
    • The use of 2-acyl-indole derivatives (including aza analogs) (I) as antitumor agents is new. Most compounds (I) are new. The use of indole derivatives of formula (I) (including their stereoisomers, tautomers, mixtures and salts) is claimed in the preparation of medicaments for treating tumor diseases. R1 = H, alkylcarbonyl, alkyl, alkylamino-T-, dialkylamino-T- (where the dialkylamino group may form a ring, optionally containing one or more NH, N(alkyl), O or S members), arylalkyl or arylalkoxyalkyl; T = 1-4C alkyl; R2 = H, halo, CN or NO2, alkyl or alkoxy (both optionally substituted (os) by one or more halo), or alkenyl, alkynyl, cycloalkyl, alkoxy, alkoxycarbonyloxy, alkylcarbonyloxy, ST, SOT, SO2T, alkoxyalkyl, NH2, alkylamino, dialkylamino (possibly forming a ring as in R1), aryl, aryloxy, aryl-T-, aryl-T-O-T-, alkylcarbonyl, alkoxycarbonyl or OH; A1-A4 = C-R3 or N; R3 = H, halo, CN or NO2, alkyl or alkoxy (both os by one or more halo); or alkenyl, alkynyl, cycloalkyl, alkoxy, 1-6C alkylenedioxy, alkoxycarbonyloxy, alkylcarbonyloxy, ST, SOT, SO2T, COOH, alkoxycarbonyl, CONH2, CONHT, CON(T)2, alkoxyalkyl, NH2, alkylamino, dialkylamino (possibly forming a ring as in R1), aryl, aryloxy, aryl-T-, aryl-T-O-T-, alkylcarbonyl or OH, or two adjacent R3 groups may be bonded, specifically as 1-6C alkylenedioxy; Y = aryl (preferably phenyl or naphthyl), 1-13C heteroaryl (containing 1-4 of N, NH, N(alkyl), O and/or S as ring members) or cycloalkyl, all os by one or more Q; Q = halo, CN, cyanoalkyl, OH, mono- or polyhydroxyalkyl, COOH, alkoxycarbonyl, CONH2, alkylcarbamoyl, CON(T)2, NO2, alkyl or alkoxy (both os by one or more halo), alkenyl, alkynyl, cycloalkyl, SH, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxyalkyl, NH2, alkylamino, dialkylamino (possibly forming a ring as in R1), aryl, aryloxy, arylalkyl, arylalkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, mono- or dialkylcarbonylamino, mono- or dialkoxycarbonylamino, N-alkylcarbonyl-N-alkylamino, N-alkoxycarbonyl-N-alkylamino, NHCHO or CHO; or two adjacent Q groups may be bonded, specifically as 1-6C alkylenedioxy, and X = O, S, NH or (H, OH); unless specified otherwise, alkyl moieties have 1-6C, alkenyl or alkynyl moieties 2-6C, cycloalkyl moieties 3-8C and aryl moieties 6-14C. Independent claims are included for the following: (a) new (I) (including their stereoisomers, tautomers, mixtures and salts), with the exception of (I; R1, R2 = H; A1, A3, A4 = CH; X = O or (if A2 = CH) CH(OH); Y = 3-carboxy-pyridin-4-yl; A2 = CH or C(OMe)), 2-cyclopropylcarbonyl-indole and 2-cyclohexylcarbonyl-indole; and (b) preparation of the new compounds (I).
    • 8. 发明专利
    • Antitumor agents having antimitotic and tubulin polymerization inhibiting action, comprising new or known 2-acyl-indole derivatives or aza analogs
    • DE10102629A1
    • 2002-07-25
    • DE10102629
    • 2001-01-20
    • ASTA MEDICA AG
    • BECKERS THOMASBAASNER SILKEKLENNER THOMASMAHBOOBI SIAVOSHPONGRATZ HERWIGFRIESER MARKUSHUFSKY HARALDHOCKEMEYER JOERGFIEBIG HEINZ-HERBERTBURGER ANGELIKABOEHMER FRANK-D
    • A61K31/404A61K31/437A61K31/4439A61K31/4709C07D209/12A61K31/519A61K31/53C07D215/14C07D401/06C07D471/04C07D487/04
    • The use of 2-acyl-indole derivatives (including aza analogs) (I) as antitumor agents is new. Most compounds (I) are new. The use of indole derivatives of formula (I) (including their stereoisomers, tautomers, mixtures and salts) is claimed in the preparation of medicaments for treating tumor diseases. R1 = H, alkylcarbonyl, alkyl, alkylamino-T-, dialkylamino-T- (where the dialkylamino group may form a ring, optionally containing one or more NH, N(alkyl), O or S members), arylalkyl or arylalkoxyalkyl; T = 1-4C alkyl; R2 = H, halo, CN or NO2, alkyl or alkoxy (both optionally substituted (os) by one or more halo), or alkenyl, alkynyl, cycloalkyl, alkoxy, alkoxycarbonyloxy, alkylcarbonyloxy, ST, SOT, SO2T, alkoxyalkyl, NH2, alkylamino, dialkylamino (possibly forming a ring as in R1), aryl, aryloxy, aryl-T-, aryl-T-O-T-, alkylcarbonyl, alkoxycarbonyl or OH; A1-A4 = C-R3 or N; R3 = H, halo, CN or NO2, alkyl or alkoxy (both os by one or more halo); or alkenyl, alkynyl, cycloalkyl, alkoxy, 1-6C alkylenedioxy, alkoxycarbonyloxy, alkylcarbonyloxy, ST, SOT, SO2T, COOH, alkoxycarbonyl, CONH2, CONHT, CON(T)2, alkoxyalkyl, NH2, alkylamino, dialkylamino (possibly forming a ring as in R1), aryl, aryloxy, aryl-T-, aryl-T-O-T-, alkylcarbonyl or OH, or two adjacent R3 groups may be bonded, specifically as 1-6C alkylenedioxy; Y = aryl (preferably phenyl or naphthyl), 1-13C heteroaryl (containing 1-4 of N, NH, N(alkyl), O and/or S as ring members) or cycloalkyl, all os by one or more Q; Q = halo, CN, cyanoalkyl, OH, mono- or polyhydroxyalkyl, COOH, alkoxycarbonyl, CONH2, alkylcarbamoyl, CON(T)2, NO2, alkyl or alkoxy (both os by one or more halo), alkenyl, alkynyl, cycloalkyl, SH, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxyalkyl, NH2, alkylamino, dialkylamino (possibly forming a ring as in R1), aryl, aryloxy, arylalkyl, arylalkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, mono- or dialkylcarbonylamino, mono- or dialkoxycarbonylamino, N-alkylcarbonyl-N-alkylamino, N-alkoxycarbonyl-N-alkylamino, NHCHO or CHO; or two adjacent Q groups may be bonded, specifically as 1-6C alkylenedioxy, and X = O, S, NH or (H, OH); unless specified otherwise, alkyl moieties have 1-6C, alkenyl or alkynyl moieties 2-6C, cycloalkyl moieties 3-8C and aryl moieties 6-14C. Independent claims are included for the following: (a) new (I) (including their stereoisomers, tautomers, mixtures and salts), with the exception of (I; R1, R2 = H; A1, A3, A4 = CH; X = O or (if A2 = CH) CH(OH); Y = 3-carboxy-pyridin-4-yl; A2 = CH or C(OMe)), 2-cyclopropylcarbonyl-indole and 2-cyclohexylcarbonyl-indole; and (b) preparation of the new compounds (I).